The Prof G Pod with Scott Galloway
The Prof G Pod with Scott Galloway

China Decode: What's at Stake Ahead of Trump and Xi's September Meeting, and China's Biotech Surge

September 8, 2026

AI Summary

5 min read

China's Geopolitical Position Strengthens Ahead of Trump-Xi Summit

As Xi Jinping prepares to meet Donald Trump in Washington on September 24, the balance of power between the two countries has shifted notably since their last encounter. James King argues that China enters this meeting as the "senior partner" in the relationship—a claim he acknowledges was controversial when he first made it months ago but now feels more justified. The US has botched its Middle East policy, faces rising oil prices, and Trump's relations with G7 allies remain strained. Meanwhile, China has been making diplomatic running through multilateral organizations like the Shanghai Cooperation Organization (SCO), which held its latest meeting in Kyrgyzstan.

Continue reading the full summary in the app — free to try.

Read Full Summary →

Free • No credit card required

Listen to Audio Summary Open in App

What you'll learn

  • 1 (02:28) **Trump-Xi Washington Summit Preview** - The hosts set up the September 24 meeting between Trump and Xi, framing it as a key test of US-China dynamics
  • 2 (10:18) **"Nothing Burger" or Real Leverage?** - Alice pushes back on the summit's significance, while James argues China holds the biggest stick
  • 3 (14:46) **AI Cooperation and Biosecurity Risks** - The hosts explore potential US-China collaboration on AI governance
  • 4 (20:15) **China's Biotech Surge: From APIs to Innovation** - Introduction of Ruby Wong, author of *China Cure*, to discuss the pharmaceutical industry's transformation
  • 5 (26:33) **China's 30% Innovation Target by 2030** - James questions whether China can produce 30% of global novel drugs by 2030
  • 6 (31:28) **What Western Pharma Wants from China** - Ruby explains the attraction of Chinese drug assets
  • 7 (34:02) **The Patent Cliff Opportunity** - James asks if China can capitalize on $400 billion in expiring drug patents by 2030

+ Full timestamped outline available in the app

Guests on this episode

James King Alice Hand

Show Notes

Alice Han and James Kynge look ahead to Trump and Xi's September 24 meeting in Washington, set against a busy stretch of Xi diplomacy, from the SCO summit to a first-ever trip to India, plus talk of a possible Trump-Putin-Xi trilateral in November. They dig into how trade, rare earths, and soybean purchases are shifting the leverage between the two powers, and whether the fight over AI dominance deserves more attention than the trade deficit.

Then: Ruby Wang, author of China Cure: The Rise of a Biotech, AI Medicine and Global Health Superpower, joins to unpack China's rapid rise in pharmaceuticals — from faster, cheaper clinical trials to a wave of global licensing deals now worth tens of billions of dollars. She explains what changed since China was a clear follower in the market as recently as 2010, and what it means for U.S. pharma competitiveness.

Subscribe to China Decode on Substack for weekly analysis, livestreams, and deep dives into the biggest story shaping the global economy: chinadecode.profgmedia.com.

Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Prof G Pod with Scott Galloway

More from this podcast

The Prof G Pod with Scott Galloway →